Our Science

OUR SCIENCE

Congress Presentations

This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.

SOHO 2025 | Houston, TX

Sep 3 - 6, 2025

Poster
ARV-393, a PROTAC BCL6 Degrader, in Preclinical Models of Diffuse Large B-cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular Lymphoma

A Van Acker et al.

VIEW MATERIAL

ICML 2025 | Lugano, Switzerland

Jun 17 - 21, 2025

Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models

A Van Acker et al.

VIEW MATERIAL

EHA 2025 | Milan, Italy

Jun 12 - 15, 2025

Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular Lymphoma

A Van Acker et al.

VIEW MATERIAL

ASCO 2025 | Chicago, IL

May 30 - Jun 3, 2025

Presentation
Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study

EP Hamilton et al.

VIEW MATERIAL
VIEW SUMMARY

ASCPT 2025 | Washington, DC

May 28 - 31, 2025

Poster
The Effect of Carbamazepine on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Healthy Adults

H Wang et al.

VIEW MATERIAL

IAPRD 2025 | New York City, NY

May 7 - 10, 2025

Poster
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Volunteers

L Smits et al.

VIEW MATERIAL

AACR 2025 | Chicago, IL

Apr 25 - 30, 2025

Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models

A Van Acker et al.

VIEW MATERIAL

AD/PD 2025 | Vienna, Austria

Apr 1 - 5, 2025

Presentation
First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Volunteers

L Smits et al.

VIEW MATERIAL

SABCS 2024 | San Antonio, TX

Dec 10 - 13, 2024

Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Abemaciclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Preliminary Phase 1b Results

J Hilton et al.

VIEW MATERIAL
VIEW SUMMARY
1 2 3 4 5 6 … 10